A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study evaluated the safety, pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Kathleen, Berger, Scott, Thorn, Katie, Taylor, Peter C., Peterfy, Charles, Siddall, Hilary, Tompson, Debra, Wang, Susanne, Quattrocchi, Emilia, Burriss, Susan W., Walter, Jochen, Tak, Paul Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962407/
https://www.ncbi.nlm.nih.gov/pubmed/33726834
http://dx.doi.org/10.1186/s13075-021-02468-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962407/
https://www.ncbi.nlm.nih.gov/pubmed/33726834
http://dx.doi.org/10.1186/s13075-021-02468-0

Ejemplares similares